Infinity Pharmaceuticals, Inc. announced the appointment of Richard Gaynor, M.D. to its Board of Directors, effective March 16, 2020. Richard Gaynor, M.D. is currently the President of Research and Development for Neon Therapeutics. Prior to his tenure at Neon Therapeutics, Dr. Gaynor spent 15 years in a series of senior roles at Lilly Oncology, most recently as Senior Vice President Clinical Development and Medical Affairs, where he chaired the Lilly Oncology Research and Development Committee and helped oversee a variety of collaborations, including with Bristol-Myers Squibb, Merck, AstraZeneca and GE.